Clinical trial
Chemotherapy Plus Vaccination to Treat Mantle Cell Lymphoma
NCT00005780 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00005780 |
|---|---|
| Title | Chemotherapy Plus Vaccination to Treat Mantle Cell Lymphoma |
| Official title | Pilot Study of Idiotype Vaccine and EPOCH-Rituximab Chemotherapy in Untreated Mantle Cell Lymphoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Mantle Cell Lymphoma, Lymphoma, Mantle Cell |
| Intervention type | Biological, Drug |
| Interventions | EPOCH-R, GM-CSF, Idiotype vaccine |
| Enrollment | 26 |
| Start date | Jun 1, 2000 |
| Primary completion | Jun 9, 2021 |
| Completion | Jun 16, 2021 |
| First posted | Jun 5, 2000 |
| Last update posted | Jan 31, 2023 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: